Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
36 studies found for:    Holden Comprehensive Cancer Center | Open Studies
Show Display Options
Rank Status Study
21 Recruiting Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: bevacizumab;   Drug: carboplatin;   Drug: everolimus;   Drug: paclitaxel
22 Recruiting Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Procedure: therapeutic thoracoscopy;   Procedure: videothoracoscopy
23 Unknown  A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: Lovastatin and Paclitaxel
24 Recruiting Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy APP21
Condition: Recurrent Prostate Cancer
Intervention: Biological: Adenovirus/PSA Vaccine
25 Recruiting [F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers
Conditions: Uterine Cervical Neoplasms;   Endometrial Neoplasms;   Anus Neoplasms;   Rectal Neoplasms;   Prostatic Neoplasms
Intervention: Radiation: Bone marrow sparing IMRT radiation therapy
26 Recruiting Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML
Condition: Acute Myeloid Leukemia
Intervention: Drug: Lovastatin and Cytarabine
27 Recruiting Gemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer, Phase I
Condition: Pancreatic Neoplasms
Interventions: Drug: Ascorbate;   Drug: Gemcitabine;   Radiation: Radiation therapy
28 Recruiting A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme
Conditions: Glioblastoma;   GBM;   Glioblastoma Multiforme
Interventions: Drug: Ascorbate;   Drug: Temozolomide;   Radiation: Radiation therapy
29 Recruiting Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat
Condition: Metastatic Melanoma
Intervention: Drug: Temozolomide, Decitabine, Panobinostat
30 Recruiting Safety and Efficacy of CML Patients Who Switch to Nilotinib and Stop Treatment After Achieving and Sustaining MR4.5.
Condition: CML
Intervention: Drug: AMN107
31 Recruiting Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study
Condition: Myelodysplastic Syndromes
Interventions: Drug: Deferasirox;   Drug: Deferasirox placebo
32 Recruiting Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
Condition: Metastatic or Unresectable Cutaneous Melanoma
Interventions: Drug: MEK162;   Drug: Dacarbazine
33 Recruiting Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Biological: Elotuzumab;   Drug: Bortezomib;   Drug: Dexamethasone
34 Recruiting LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: LDK378;   Drug: pemetrexed;   Drug: docetaxel
35 Recruiting A Study of Abemaciclib (LY2835219) in Participants With Previously Treated Lung Cancer
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Abemaciclib;   Drug: Erlotinib
36 Recruiting A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153)
Condition: Non Small Cell Lung Cancer (NSCLC)
Intervention: Drug: Nivolumab

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-36) Next Page   
Indicates status has not been verified in more than two years